| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | ramucirumab (Cyramza®) |
| Formulation | intravenous infusion |
| Reference number | 2536 |
| Indication | In combination with docetaxel for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/02/2016 |
| NICE guidance | TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |